Background: Progressive/recurrent high-grade and diffuse intrinsic pontine gliomas (DIPGs) are fatal. Treatments targeting molecular pathways critical for these cancers are needed.
INTRODUCTION
High-grade gliomas (HGGs), including diffuse intrinsic pontine gliomas (DIPGs), are among the most aggressive and lethal primary central Abbreviations: CNS, central nervous system; DIPG, diffuse intrinsic pontine glioma; DLT, dose-limiting toxicity; HGF, hepatocyte growth factor; HGG, high-grade glioma; HRQoL, health-related quality of life; MTD, maximum tolerated dose; PBMC, peripheral-blood mononuclear cells; PDGFR, platelet-derived growth factor receptor; RT, radiation therapy nervous system (CNS) tumors in children. 1 The prognosis of affected patients remains dismal despite treatment with maximum safe surgical resection, radiation therapy (RT), and chemotherapy. 1 cancers, which are mostly different from adult tumors. [2] [3] [4] [5] [6] Second, the establishment of preclinical models, including cell lines and human xenografts, has allowed for the high-throughput screening of new promising agents. 7 Therapies targeting abnormally activated cellular pathways have shown promising activity against preclinical models of pediatric HGGs and DIPGs including inhibitors of platelet-derived growth factor receptor (PDGFR) and c-Met. [7] [8] [9] The PDGF pathway influences tumor formation by stimulating mitogenesis, dedifferentiation, and increased angiogenesis, and its modulation in vivo in combination with other oncogenic abnormalities led to the formation of HGGs and DIPGs in preclinical models. [10] [11] [12] [13] While PDGFRA amplification can be found in one-third and 19% of DIPGs and pediatric nonbrainstem HGGs, respectively, 2, 6 PDGFRA mutations occurred in approximately 5% and 14% of such tumors, respectively. 12 Activation of the c-Met pathway has been recognized as a contributing mechanism for the formation of HGGs. 14 MET is the second most common amplified oncogene in DIPG. 2 MET fusion transcripts have recently been identified in approximately 10% of pediatric glioblastomas (WHO grade IV), particularly in those originating from the cerebral hemispheres. 9 MET fusion transcripts in combination with other oncogenic mechanisms also led to the formation of HGGs in an in vivo preclinical model. 9 Finally, cell lines and xenografts containing MET fusion transcripts were responsive to c-Met inhibition. 9 Dasatinib (Sprycel, Bristol-Myers Squibb) is a potent oral inhibitor of PDGFRA and B, Src, and c-Kit, for which a phase 2 single-agent recommended dose has already been established in children. 15 Crizotinib (Xalkori, Pfizer) is a potent inhibitor of ALK and c-Met that has already undergone phase 1 testing in children. 16 Based on previously described data, we initiated a phase 1 clinical trial to test the tolerability and safety, and to establish the maximum tolerated dose (MTD) of the combination of dasatinib and crizotinib in pediatric patients with recurrent or progressive HGGs and DIPGs.
PATIENTS AND METHODS
Patients between the ages of 2 and 21 years old with clinically and/or radiologically recurrent or progressive HGG or DIPG were eligible for this study. Other inclusion criteria consisted of the following: (1) performance score ≥ 50; (2) adequate hematologic (hemoglobin ≥ 8 g/dl [irrespective of previous transfusions], absolute neutrophil count ≥ 1,000/mm 3 , and platelet count ≥ 100,000/mm 3 [transfusion independent]), renal (normal serum creatinine for age), and hepatic (transaminases and bilirubin <3× and <1.5× the institutional upper limit of normal, respectively, and albumin ≥ 2 g/dl) functions; (3) stable neurologic deficits on a fixed or decreasing dose of dexamethasone for ≥1 week; (4) no more than a grade 1 toxicity attributed to previous therapies; (5) interval from previous local, craniospinal, and palliative RT of ≥3 months, ≥6 months, and ≥2 weeks, respectively; (6) interval ≥ 4 weeks from previous chemotherapy (6 weeks if nitrosourea); (7) interval ≥ 1 week from previous small-molecule inhibitors with short half-lives; (8) interval ≥ 3 half-lives from previous monoclonal antibodies; (9) interval ≥ 3 months from previous high-dose chemotherapy with stem-cell rescue; (10) interval ≥ 1 week and ≥ 2 weeks from the use of filgrastim and pegfilgrastim, respectively; and (11) effective contraception for females of childbearing age and males of child fathering potential. Exclusion criteria consisted of the following: (1) use of other anticancer therapies; (2) use of enzyme-inducing anticonvulsants less than 10 days before start of protocol therapy; (3) previous treatment with a PDGFR or c-Met inhibitor; (4) presence of other medical conditions that could interfere with the study procedures or tolerance to therapy; and (5) pregnant or lactating patients.
Our institutional review board approved this protocol before initial patient enrollment, and continuing approval was maintained throughout the study. Written informed consent for participation was obtained from patients' parents or legal guardians, and assents were obtained when appropriate.
Study design
This single-institution clinical trial followed the rolling-six design. The MTD was defined as the highest dosage at which no more than one of six evaluable patients experienced a dose-limiting toxicity (DLT).
Two regimens of this combination were tested. Dasatinib and crizotinib were initially administered twice daily and the DLT evaluation period (Table 1 ). In both regimens, patients received the first dose of crizotinib on day 1 and then treatment was held for 48 hr to allow for completion of pharmacokinetic studies. The administration of dasatinib was delayed for 48 hr as well.
Treatment with both drugs continued uninterrupted on day 3 of therapy except for the omission of the evening dose of crizotinib on day 14 in the twice-daily regimen so that extended pharmacokinetic studies could be completed.
Treatment was divided into 28-day cycles except for the first two cycles on the twice-daily regimen that comprised 6 weeks. The maximum planned treatment duration was 2 years. An echocardiogram was obtained before the start of therapy, at the completion of cycle 1, and every 6 months thereafter during treatment. Chest X-ray was obtained before the start of therapy and every 6 months thereafter.
Pharmacokinetic studies
For the twice-daily regimen, mandatory pharmacokinetic studies of crizotinib were scheduled on days 1 and 14, and studies of crizotinib and dasatinib were to occur approximately at the end of the DLTevaluation period (day 42 ± 3 days). In the once-daily regimen, the pharmacokinetic studies of crizotinib were scheduled on days 1 and 14, and the pharmacokinetic studies of dasatinib occurred on day 14. 
Pharmacodynamic studies
Optional studies consisted of serial evaluation of the plasma concentration of the hepatocyte growth factor (HGF) obtained concurrently with brain MRIs before the start and during therapy, and analysis of total and phosphorylated AKT and ERK in peripheral-blood mononuclear cells (PBMCs) obtained before and 3 hr after the administration of dasatinib on day 14 of therapy and at the end of the DLT-evaluation
period. Details about sample processing, collection, and analysis are provided in Supplementary Appendix S1.
Molecular studies
Analysis of amplification of PDGFRA and MET by FISH was performed as previously described. 17 The methods used for PDGFRA sequencing are provided in Supplementary Appendix S1.
Assessment of quality of life
Health-related quality of life (HRQoL) was assessed through patient and parent-proxy report using the Pediatric Quality of Life Inventory (PedsQL 4.0) and the Pediatric Quality of Life Brain Tumor Module (PedsQL BT module). 18, 19 Patients and parent-proxy reported on HRQoL and symptoms over the previous 7 days. The HRQoL assessments were obtained at the initiation of therapy, at weeks 2, 4, and 6 of therapy, and before every other cycle of therapy beginning at cycle 3.
Statistical analysis
Descriptive statistics were provided. Random coefficient model was used to test whether HGF concentration changed with time. The
Spearman correlation was used to estimate the association between HGF plasma concentrations and length of therapy. Sign test, a nonparametric analog of the t-test for paired samples, was used to compare p-ERK/total ERK (or p-AKT/total AKT) before and after administration of dasatinib, and to compare data obtained after administration of dasatinib on different days. A significance threshold of 0.05 was used without adjusting for multiplicity.
The Wilcoxon signed-rank test was used to compare the change in
HRQoL from baseline to week 2, week 2 to week 4, and week 4 to week 6 of therapy for patients and parents. Patient (≥5 years of age)
self-reported and parent-proxy reported HRQoL domain scores were compared at each therapy time point using the Wilcoxon signed-rank test, with data only reported for patients and parents with comparative data. The false discovery rate adjustment was used to account for multiple testing when appropriate. A two-sided significance level of P < 0.05 was used for all statistical tests. Statistical analyses were conducted using SAS Version 9.4 (SAS Institute, Cary, NC). 
TA B L E 2 Characteristics of 25 patients enrolled in this study
Of note, 11 patients had a radiologic diagnosis of diffuse intrinsic pontine glioma. Three patients with diffuse intrinsic pontine glioma had histologic confirmation at biopsy (n = 2) or at autopsy (n = 1).
RESULTS
Twenty-five patients were enrolled in this study from November 2012 until September 2016. Tables 2 and 3 list their characteristics at study enrollment. All patients except one had measurable radiographic disease at the start of this therapy. Three (12%) of 25 patients had leptomeningeal metastases at the start of therapy although complete metastatic work-up was not mandatory.
Of five patients enrolled on dosage level 1 of the twice-daily regimen, three of four evaluable patients experienced DLTs consisting of grade 3 diarrhea (n = 1) and fatigue (n = 2). Therefore, three patients started treatment on dosage level 0, two of whom developed DLTs. One patient experienced grade 3 hyponatremia concurrently with disease progression; further evaluation showed that hyponatremia was at least partially related to inappropriate secretion of antidiuretic hormone.
Another patient with normal urinalysis at the start of therapy developed grade 3 proteinuria within the nephrotic range which improved with discontinuation of treatment.
Since the twice-daily regimen was poorly tolerated even at the lowest planned dosage level, the clinical trial was amended to test doses of the study drugs closer to their single-agent MTD administered once daily. Six patients were enrolled on dosage level 1 of the once-daily regimen, three of whom were unevaluable due to early disease progression. None of the three evaluable patients experienced significant toxicities. Therefore, eight patients started treatment on dosage level 2a. Only one of six evaluable patients at this dosage level had a DLT consisting of grade 3 diarrhea and rash. Hence, three patients were treated at dosage level 2b, two of whom experienced DLTs consisting of grade 3 rash (n = 1) and grade 4 neutropenia (n = 1). Therefore, the MTD was established as dasatinib 50 mg/m 2 and crizotinib 215 mg/m 2 administered once daily. Table 4 
Pharmacokinetic studies
Pharmacokinetic studies of crizotinib were collected from 25 patients Table 5 .
Pharmacodynamic studies
Twenty-one patients had 46 serial plasma samples analyzed for the concentration of HGF (median = 198.3 pg/ml; range: 88.1-3,925.8).
There was no change in the log-transformed concentration of HGF in plasma over time for patients with serially collected samples (P = 0.087). We found a negative correlation between HGF plasma con- 
TA B L E 3 Clinical and molecular data for all 25 patients
Gender/race or ethnicity 
Molecular studies
Seventeen patients underwent histologic confirmation of their tumors.
Of 10 (59%) tumors that could undergo sequencing, only one harbored a nonsynonymous PDGFRA mutation (c.1432T > C p.S478P).
FISH analysis of PDGFRA and MET amplifications were available in 16 (94%) cases. While four tumors harbored PDGFRA amplification, one of them focal, MET amplification occurred in two cases. Only one tumor harbored co-amplification of both oncogenes (Table 3) .
Outcome
The median number of cycles of therapy received was one (range: 0-12). Seven patients experienced clinical progression before completion of cycle 1 of therapy. Only two patients received at least six cycles of therapy (Table 3) . No objective radiologic responses were observed with this therapy. Only three patients remain alive.
Quality of life
HRQoL measures were collected from 23 patients. Only median total scores were reported due to the small sample size. We included evaluations up to week 6 of therapy because by that time point only nine participants remained in the study. Only the physical, emotional, and social domains were reported for the PedsQL 4.0, as these patients were not attending school.
Patients reported physical function decline starting at week 6 of treatment. Patients did not report a significant increase in brain tumorspecific symptom scores through the first 6 weeks of therapy. Parentproxy reports were then compared to those obtained from patients.
Parent-proxy reported their child as having significantly lower physical function at week 6 and significantly lower emotional and social function at baseline and at weeks 2 and 4 compared to patients' report.
Parent-proxy reported their child as experiencing poorer cognitive function at weeks 2 and 4, more pain and hurt at week 2, poorer movement and balance at baseline and at weeks 2 and 4, more nausea at week 4, more worry at baseline and at week 2, and overall lower TA B L E 4 Most significant toxicities attributed to study agents during and after DLT-evaluation period Of note, results are shown as median (ranges in parentheses). AUC 0→t of crizotinib were t = ∞ for day 1 and t = 24 hr for day 14.
HRQoL from baseline until week 4 when compared to the patients' reports.
DISCUSSION
The rational design of innovative clinical trials using small-molecule We report detailed clinical, pharmacokinetic, and pharmacodynamic data about the combination of dasatinib and crizotinib.
Unfortunately, this combination was poorly tolerated and the recommended daily phase 2 dose represented 29% and 38% of the MTD of dasatinib and crizotinib, respectively, when used as single agents in children with solid tumors. 15, 16 Most of the toxicities observed, including diarrhea, nausea and vomiting, electrolyte abnormalities, rash, and hypoalbuminemia were predictable based on the adverse events previously reported with these medications. 15, 16 However, the observation of severe proteinuria in the nephrotic range and hyponatremia was unexpected. No objective radiologic responses were observed.
Although we initially designed our pharmacokinetic studies to evaluate potential interactions between dasatinib and crizotinib, the limited number of patients evaluated prevented us from drawing firm conclusions. The C max and AUC of dasatinib in our patients showed similar results to those previously reported in children with DIPG. 20 Likewise, several pharmacokinetic parameters of crizotinib in our patients (for example, C max , T max , AUC 0→t , and apparent oral clearance)
were comparable to those reported recently in children with solid tumors despite significant methodologic differences between both studies (for example, drug formulation and pharmacokinetic sampling strategy). 21 Our results demonstrating a decrease in p-AKT in PBMC after administration of dasatinib are interesting, although significant concern remains that dasatinib does not reach clinically effective concentrations in the CNS. 20, 22 The longitudinal analysis of plasma HGF was performed based on the report that its expression was predictive of response to c-Met inhibition in HGG preclinical models. 23 Future studies using c- shown activity of this agent, which seems to be mostly cytostatic. 8, 12, 24 However, the promiscuity of dasatinib in inhibiting multiple targets probably accounts for a large share of its toxicities. Furthermore, as a substrate of p-glycoprotein and BCRP, 22 it is now recognized that its CNS penetration is more limited than initially recognized. 20 Finally, the recommended phase 2 dose reached in this clinical trial provided short exposure to this agent considering that its t 1/2 is quite short. 20 Likewise, crizotinib was the only c-Met inhibitor commercially available at the start of this study. Although there was anecdotal evidence of its activity against MET-amplified glioblastoma, 25 it is now clear that the CNS penetration of crizotinib is minimal and probably inadequate for the treatment of primary CNS cancers. 25, 26 One study recently reported promising activity of the combination of dasatinib and cabozantinib, another c-Met inhibitor, against DIPG-derived cell lines. 8 We believe that specific and better CNS-penetrant PDGFRA and cycles, we were unable to sequence PDGFRA in his tumor. We were unable to evaluate tumors for the recently described MET fusions either. 9 Based on the data provided, particularly the significant toxicity and low recommended phase 2 dose, we do not feel that further testing of the combination of dasatinib and crizotinib in children with CNS cancers is warranted.
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